Home / Markets / Industries / Health Care
- Business Leaders
- Commodities
- Economy
- Market Overview
- Mutual Funds & ETFs
- Industries
- Innovation
- America's Road to Recovery
- America's Infrastructure
-
Friday, November 20, 2009
A European advisory committee has recommended approval for Merck & Co.'s (MRK) new fertility drug Elonva.
-
Friday, November 20, 2009
-
Friday, November 20, 2009
-
Friday, November 20, 2009
-
Thursday, November 19, 2009
China Medical Technologies Inc. (CMED) shares fell Thursday after the company posted a quarterly loss.
More News
- Allergan, Medicis Lead Drug Stocks Lower
- Patterson Companies Net Income Up 5%
- UK Health Unit Rejects Bayer Drug As Too Expensive
- Reckitt Benckiser Close To Announcing Deal: Report
- Sanofi-Aventis To Launch Antimalarial Drug Study
- AstraZeneca Submits Brilinta NDA To FDA
- READ: The Senate's Health-Care Reform Bill
- Japan Shares Fall, Taking Cue From Wall Street
- Senate Health Bill To Cost $849 Billion: Report
- Vivus Shares Rise on Erectile Dysfunction Drug Success
Press Releases
- River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries
- Alnylam Pharmaceuticals Down 21.5% Since SmarTrend's Sell Recommendation
- Origin Agritech Announces Final Approval of World's First Genetically Modified Phytase Corn
- Glancy Binkow & Goldberg LLP Appointed Co-Lead Counsel In Skilled Healthcare Group, Inc. Securities Class Action
- Escalon(R) Reports First Quarter Fiscal 2010 Results
- U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
- U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
- Importance of Real-Time CPR Feedback Presented at AHA Scientific Sessions 2009
- NUCRYST Announces Special Meeting of Shareholders
- NUCRYST Announces Special Meeting of Shareholders
